DOCSLIB.ORG

Semi-Bulk Products CAS ACACIA POWDER 9000-01-5 ACCOFLOC A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Semi-Bulk Products CAS ACACIA POWDER 9000-01-5 ACCOFLOC A Semi-Bulk Products CAS ACACIA POWDER 9000-01-5 ACCOFLOC A 110H NA ACENAPHTHENE 83-32-9 ACES 7365-82-4 ACETAL 105-57-7 ACETALDEHYDE OXIME 107-29-9 ACETAMIDE 60-35-5 ACETAMIDE OXIME 22059-22-9 ACETAMIDINE HYDROCHLORIDE 124-42-5 5-ACETAMIDO-2-BROMOBENZOIC ACID 22921-67-1 ACETANILIDE 103-84-4 ACETOACETANILIDE 102-01-2 ACETOBROMO-A-D-GLUCOSE 572-09-8 ACETOGUANAMINE 542-02-9 ACETOHYDROXAMIC ACID 546-88-3 ACETOIN 513-86-0 ACETONITRILE 75-05-8 ACETOPHENONE 98-86-2 2-ACETOXYACETOPHENONE 7250-94-4 ACETOXYACETYL CHLORIDE 13831-31-7 4-ACETOXYBENZALDEHYDE 878-00-2 (3S,4R)-4-ACETOXY-3(R)-(T-BUTYLDIMETHYLSILYOXYETHYL)-2-AZETIDIONE 76855-69-1 ACETOXY ISOBUTYRYL BROMIDE 40635-67-4 ACETURIC ACID 543-24-8 ACETYLACETONE 123-54-6 3-ACETYLBENZONITRILE 6136-68-1 4-ACETYLBENZONITRILE 1443-80-7 2-ACETYL-5-BROMOTHIOPHENE 5370-25-2 N-ACETYL-Y-BUTYROLACTONE 517-23-7 1-ACETYL-4-(2-CHLOROETHYL)PIPERAZINE HYDROCHLORIDE 92928-18-2 N-ACETYL-L-CYSTEINE 616-91-1 3-O-ACETYL-1,2,5,6-DI-O-ISOPROPYLIDENE-A-D-GLUCOFURANOSE 16713-80-7 ACETYLENE DICARBOXYLIC ACID MONO POTASSIUM SALT 928-04-1 N-ACETYL-D-GALACTOSAMINE 14215-68-0 N-ACETYL-D-GLUCOSAMINE 7512-17-6 N-ACETYL-D-GLUTAMIC ACID 19146-55-5 N-ACETYL-L-GLUTAMIC ACID 1188-37-0 N-ACETYL-L-GLUTAMINE 2490-97-3 N-ACETYLGLYCINE 543-24-8 1-ACETYLGUANIDINE 5699-40-1 N-ACETYL-4(4-HYDROXYPHENYL) PIPERAZINE 67914-60-7 N-EPSILON-ACETYL-L-LYSINE 692-04-6 N-ACETYL-DL-METHIONINE 1115-47-5 2-ACETYL-6-METHOXYNAPHTHALENE 3900-45-6 N-ACETYLNEURAMINIC ACID 131-48-6 4-ACETYLPHENOXYACETIC ACID 1878-81-5 N-ACETYLPHENYL HYDRAZINE 114-83-0 2-ACETYLPYRIDINE 1122-62-9 3-ACETYLPYRIDINE 350-03-8 5-ACETYLSALICYLAMIDE 40187-51-7 ACETYLSALICYLIC ACID 50-78-2 ACETYLTETRALENE 774-55-0 2-ACETYLTHIOPHENE 88-15-3 ACETYL TRIBUTYL CITRATE 77-90-7 N-ACETYL-DL-TRYPTOPHAN 87-32-1 N-ACETYL-L-TYROSINE 537-55-3 ACID FUCHSIN 3244-88-0 ACID VIOLET ANTHRAQUINONE 63310-00-9 ACID YELLOW 99 10343-58-5 CIS-ACONITIC ACID 585-84-2 ACRIDINE ORANGE C.I.46005 10127-02-3 ACRIDINE RED B NA ACRYLAMIDE 79-06-1 2-ACRYLAMIDO-2-METHYLPROPANE 15214-89-8 ACRYLAMIDO-2-METHYLPROPANE SULFONIC ACID 15214-89-8 ACTICIDE BW-20 NA 2-ADAMANTANAMINE HYROCHLORIDE 10523-68-9 ADAMANTANE 281-23-2 1-ADAMANTANOL 768-95-6 2-ADAMANTANONE 700-58-3 2-ADAMANTYLAMINE HYDROCHLORIDE ADENINE SULFATE 321-30-2 ADENOSINE 58-61-7 ADENOSINE-5'-DIPHOSPHATE DISODIUM SALT 16178-48-6 ADENOSINE-5-DIPHOSPHATE POTASSIUM SALT 72696-48-1 ADENOSINE-5-MONOPHOSPHATE 18422-05-4 ADENOSINE-5-'-MONOPHOSPHATE DISODIUM SALT 4578-31-8 ADENOSINE-5-MONOPHOSPHORIC ACID DISODIUM 4578-31-8 ADENOSINE-5-TRIPHOSPHATE DISODIUM 51963-61-2 ADIPIC ACID 124-04-9 ADRENALINE BASE 148-72-1 AEROSIL R972 60842-32-2 AGAR POWDER 9002-18-0 AGAROSE 9012-36-6 AGAROSE D-1 HIGH EEO 9012-36-6 B-ALANINE 107-95-9 D-ALANINE 338-69-2 DL-ALANINE 302-72-7 L-ALANINE 56-41-7 B-ALANINE ETHYLESTER HYDROCHLORIDE 4244-84-2 L-ALANINE ETHYLESTER HYDROCHLORIDE 1115-59-9 L-ALANINE ISOPROPYL ESTER HYDROCHLORIDE 62062-65-1 D-ALANINE METHYLESTER HYDROCHLORIDE 14316-06-4 DL-ALANINE METHYLESTER HYDROCHLORIDE 13515-97-4 L-ALANINOL 2749-11-3 ALAR B-9 ALBUMIN EGG FLAKES 9006-59-1 CRYSTAL ALBUMIN ALGINIC ACID 9005-32-7 ALIZARIN 72-48-0 ALIZARIN BLUE CI: 16680 ALIZARIN COMPLEXONE 3952-78-1 ALKYLDIMETHYLAMINE OXIDE (GENAMINOX CSL) 61788-90-7 ALLANTOIN 97-59-6 ALLOPURINOL 315-30-0 ALLYLALCOHOL 107-18-6 ALLYLBROMIDE 106-95-6 ALLYLCAPROATE 123-68-2 ALLYL METHACRYLATE 96-05-9 N-ALLYLTHIOUREA 109-57-9 ALLYLTRIBUTYLTIN 24850-33-7 ALMOND OIL 8007-69-0 ALOE BP NA ALOIN NA ALUMINA 1344-28-1 ALUMINIUM METAL 7429-90-5 ALUMINIUM AMMONIUM SULFATE 7784-26-1 ALUMINIUM CHLORIDE ANHYDROUS 7446-70-0 ALUMINIUM CHLOROHYDRATE 1327-41-9 ALUMINIUM FLUORIDE 7784-18-1 ALUMINIUM HYDROXIDE 21645-51-2 ALUMINIUM OXIDE 1344-28-1 ALUMINIUM OXIDE ACTIVE BASIC 1344-28-1 ALUMINIUM OXIDE ACTIVE NEUTRAL 1344-28-1 ALUMINIUM POTASSIUM SULFATE 7784-24-9 ALUMINIUM SULFATE 7784-31-8 AMARANTH 915-67-3 AMBERLITE IR-120 68441-33-8 / 78922-04-0 AMBERLITE IRA-120 H NA AMBERLITE IRA-120 Na NA AMBERLITE IRA-35 76930-03-5 AMBERLITE IRA-400 9002-24-8 / 60177-39-1 AMBERLITE IRC-50 9002-29-3 AMBERLITE IRC-748 9002-29-3 AMBERLITE IRN 150 79956-14-2 AMBERLITE XAD-2 9060-05-3 AMBERLYST 15 39389-20-3 AMBERLYST R-15(I) NA AMIKACIN 37517-28-5 (anhydrous) AMILORIDE HYDROCHLORIDE 2016-88-8 N-Z-AMINE TYPE B (ENZYMATIC DIGEST OF CASEIN) NA AMINOACETALDEHYDE DIMETHYLACETAL 22483-09-6 4-AMINOACETANILIDE 122-80-5 AMINOACETONITRILE HYDROCHLORIDE 6011-14-9 3-AMINOACETOPHENONE 99-03-6 4-AMINOACETOPHENONE 99-92-3 4-AMINOANTIPYRINE 83-07-8 4-AMINOBENZAMIDE 2835-68-9 5-AMINOBENZIMIDAZOLONE 95-23-8 2-AMINOBENZOIC ACID 118-92-3 3-AMINOBENZOIC ACID 99-05-8 4-AMINOBENZOIC ACID 150-13-0 2-AMINOBENZONITRILE 1885-29-6 4-AMINOBENZONITRILE 873-74-5 4-AMINOBENZOPHENONE 1137-41-3 2-AMINOBENZOTRIFLUORIDE 88-17-5 4-AMINOBENZOTRIFLUORIDE 455-14-1 4-AMINOBENZOYL-L-GLUTAMIC ACID 4S-4-(4-AMINOBENZYL)-1,3-OXAZOLAN-2-ONE S-4-(4-AMINOBENZYL)-1,3-OXAZOLIDINE-2-ONE 4-AMINO-1-BENZYLPIPERIDINE 50541-93-0 2-AMINO-5-BROMO BENZOIC ACID 5794-88-7 2-AMINO-4-BROMOBENZOPHENONE 135776-98-6 2-AMINO-6-BROMOPYRIDINE 19798-81-3 2-AMINO-4-TERT-BUTYLPHENOL 1199-46-8 S-2-AMINOBUTYRAMIDE HYDROCHLORIDE 7682-20-4 4-AMINOBUTYRIC ACID 56-12-2 DL-2-AMINOBUTYRIC ACID 2835-81-6 L-(+)-2-AMINOBUTYRIC ACID 1492-24-6 6-AMINOCAPROIC ACID 60-32-2 DL-A-AMINO-E-CAPROLACTAM 17929-90-7 7-AMINO CEPHALOSPORANIC ACID 957-68-6 2-AMINO-5-CHLOROBENZOIC ACID 635-21-2 4-AMINO-2-CHLOROBENZOIC ACID METHYLESTER 46004-37-9 4-AMINO-2-CHLOROBENZONITRILE 20925-27-3 2-AMINO-5-CHLOROBENZOPHENONE 719-59-5 2-AMINO-N-2-CHLORO-6-METHYLPHENYL-THIAZOLE-5-CARBOXAMIDE 302964-24-5 2-AMINO-6-CHLOROPURINE 10310-21-1 2-AMINO-5-CHLOROPYRIDINE 1072-98-6 4-AMINO-2-CHLOROPYRIDINE 14432-12-3 3-AMINO-4-CYANOPYRAZOLE 16617-46-2 TRANS-4-AMINOCYCLOHEXANOL 27489-62-9 7-AMINODESACETOXYCEPHALOSPORANIC ACID 22252-43-3 4-AMINO-2,6-DICHLOROPYRIDINE 2587-02-2 4-AMINO-3,5-DICHLOROPYRIDINE 22889-78-7 4-AMINO-N,N,-DIMETHYLANILINE 99-98-9 AMINOETHOXYNITRO ACRIDINE 1,4-AMINO-3-FLUOROPHENYL PYRIDIN-2(1H)-ONE 536747-52-1 AMINOGUANIDINE BICARBONATE 2582-30-1 4-AMINOHIPPURIC ACID 61-78-9 (2R-CIS)-4-AMINO-1-(2-HYDROXYMETHYL)-1,3-OXATHIOLAN-5YL)-2(1H)- PYRIMIDINONE SALYCYLATE MONOHYDRATE 4-AMINO-3-HYDROXYNAPHTHALENE-1-SULFONIC ACID 116-63-2 2-AMINO-3-HYDROXYPYRIDINE 16867-03-1 5-AMINOIMIDAZOLE-4-CARBOXAMIDE 360-97-4 R-(-)-1-AMINOINDAN HYDROCHLORIDE 10305-73-4 2-AMINO-4-METHOXY-3-METHYLACETOPHENONE 912347-94-5 S-(+)-1-AMINO-2-METHOXY METHYL PYRROLIDINE 59983-39-0 4-AMINO-3-METHOXY-1-PIPERIDINE-1-CARBOXYLIC ACID ETHYL ESTER 4-AMINO-3-METHYLBENZOIC ACID 2486-70-6 2-AMINOMETHYL-3-FLUOROPYRIDINE DIHYDROCHLORIDE 312904-49-7 5-AMINO-3-METHYLISOTHIAZOLE 19947-75-2 2-AMINO-3-METHYL-5-NITROPYRIDINE 18344-51-9 2-AMINOMETHYLPHENYLACETIC ACID 40851-65-8 2-AMINO-2-METHYL-1-PROPANOL 124-68-5 2-AMINO-3-METHYLPYRIDINE 1603-40-3 2-AMINO-5-METHYLPYRIDINE 1603-41-4 2-AMINOMETHYLPYRIDINE 3731-51-9 2-AMINO-5-METHYLTHIAZOLE 7305-71-7 8-AMINONAPHTHALENE-3,6-DISULFONIC ACID SODIUM 1-AMINO-2-NAPHTHOL-4-SULFONIC ACID 116-63-2 2-AMINO-5-NITROANISOLE 97-52-9 2-AMINO-5-NITROBENZOIC ACID 616-79-5 4-AMINO-3-NITROBENZOIC ACID 1588-83-6 2-AMINO-4-NITROPHENOL 99-57-0 2-AMINO-5-NITROPHENOL 121-88-0 4-AMINO-3-NITROPHENOL 610-81-1 2-AMINO-5-NITROPYRIDINE 4214-76-0 4-AMINO-3-NITROPYRIDINE 1681-37-4 6-AMINOPENICILLANIC ACID 551-16-6 2-AMINOPHENOL 95-55-6 3-AMINOPHENOL 591-27-5 4-AMINOPHENOL 123-30-8 2,2-AMINOPHENYLETHANOL 5339-85-5 S-2-AMINO-1-PHENYLETHANOL 56613-81-1 L-2-AMINO-3-PHENYLPROPIONICACID 63-91-2 3-AMINOPHTHALHYDRAZIDE (LUMINOL) 521-31-3 2-AMINO-4-PICOLINE 695-34-1 2-AMINOPICOLINE 1-AMINOPIPERIDINE 2213-43-6 3-AMINO-1,2-PROPANEDIOL 616-30-8 3-AMINO-1-PROPANOL 156-87-6 N-3-AMINOPROPYLDIETHANOLAMINE 4985-85-7 2-AMINOPYRIDINE 504-29-0 3-AMINOPYRIDINE 462-08-8 4-AMINOPYRIDINE 504-24-5 AMINO PYRIDINE 2-AMINOPYRIMIDINE 109-12-6 5-AMINOQUINOLINE 611-34-7 6-AMINOQUINOLINE 580-15-4 3-AMINOSALICYLIC ACID 570-23-0 4-AMINOSALICYLIC ACID 65-49-6 5-AMINOSALICYLIC ACID 89-57-6 3-AMINO-1,2,4-TETRAZOLE 5-AMINO-1H-TETRAZOLE MONOHYDRATE 15454-54-3 2-AMINO-1-3-4-THIADIAZOLE 4005-51-0 2-AMINOTHIOPHENOL 137-07-5 6-AMINOTHYMOL HYDROCHLORIDE 6321-11-5 4-AMINO-1,2,4-TRIAZOLE 584-13-4 4,4-AMINO-2-TRIFLUOROMETHYLPHENYL PIPERAZINE-1-CARBOXYLIC ACID TERT 193902-87-3 BUTYL ESTER AMIODARONE HYDROCHLORIDE 19774-82-4 AMITRIPTYLENE HYDROCHLORIDE 549-18-8 AMMONIUM ACETATE 631-61-8 AMMONIUM BENZOATE 1863-63-4 AMMONIUM BICARBONATE 1066-33-7 AMMONIUM BIFLUORIDE 1341-49-7 AMMONIUM BORATE 12007-89-5 AMMONIUM CHLORIDE 12125-02-9 AMMONIUM CHROMATE 7788-98-9 TRI-AMMONIUM CITRATE 3458-72-8 AMMONIUM DICHROMATE 7789-09-5 AMMONIUM DIHYDROGEN PHOSPHATE 7722-76-1 AMMONIUM FERRIC SULFATE 7783-83-7 AMMONIUM FERROUS SULFATE 7783-85-9 AMMONIUM FLUORIDE 12125-01-8 AMMONIUM FLUORIDE 40% 12125-01-8 AMMONIUM MOLYBDATE 13106-76-8 AMMONIUM PERSULFATE 7727-54-0 AMMONIUM PHOSPHOMOLYBDATE 54723-94-3 AMMONIUM PURPURATE(MUREXIDE) 3051-09-0 AMMONIUM PYRROLIDINE DITHIOCARBAMATE 5108-96-3 AMMONIUM REINECKATE 13573-16-5 AMMONIUM SULFAMATE 7773-06-0 AMMONIUM SULFATE 7783-20-2 AMMONIUM TARTRATE 3164-29-2 AMMONIUM-P-TUNGSTATE 11120-25-5 AMMONIUM META VANADATE 7803-55-6 AMOXICILLIN 26787-78-0 / 61336-70-7 AMPICILLIN 69-53-4 AMYGDALIN 29883-15-6 N-AMYLALCOHOL 71-41-0 AMYLCINNAMLDEHYDE DIMETHYLACETAL 60763-41-9 AMYL-M-CRESOL 53043-14-4 AMYLOPECTIN 9037-22-3 ANILINE 62-53-3 ANILINE BLUE WATER SOLUBLE C.I.
Load more

Recommended publications
  • Aldrich FT-IR Collection Edition I Library
    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0156618 A1 Tollefson (43) Pub
    US 20090156618A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0156618 A1 Tollefson (43) Pub. Date: Jun. 18, 2009 (54) 1-(1-(2-ETHOXYETHYL)-3-ETHYL-7- Related U.S. Application Data (4-METHYLPYRIDIN-2-YLAMINO) - 1H-PYRAZOLO 4.3-D PYRIMIDIN-5-YL) (60) Provisional application No. 60/735,320, filed on Nov. PPERDINE-4-CARBOXYLIC ACID AND 10, 2005. SALTS THEREOF Publication Classification (51) Int. Cl. (75) Inventor: Michael B. Tollefson, Dardenne A 6LX 3/59 (2006.01) Prairie, MO (US) C07D 487/04 (2006.01) A6IP 9/12 (2006.01) A6IP 25/00 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) PFZER INC. PATENT DEPARTMENT, Bld 114 M/S 114, (52) U.S. Cl. ...................................... 514/262.1; 54.4/262 EASTERN PONT ROAD (57) ABSTRACT GROTON, CT 06340 (US) The present invention comprises 1-(1-(2-ethoxyethyl)-3- ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo 4.3-d (73) Assignee: Pfizer Inc pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts. The invention further comprises pharmaceutical composi tions, methods of treatment, and synthetic methods relating to (21) Appl. No.: 111558,306 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2- ylamino)-1H-pyrazolo 4.3-dipyrimidin-5-yl)piperidine-4- (22) Filed: Nov. 9, 2006 carboxylic acid and its salts. Patent Application Publication Jun. 18, 2009 Sheet 2 of 2 US 2009/0156618 A1 "SOIHZ US 2009/0156618 A1 Jun. 18, 2009 1-(1-(2-ETHOXYETHYL)-3-ETHYL-7- 1H-pyrazolo 4,3-dipyrimidin-5-yl)piperidine-4-carboxylic (4-METHYLPYRIDIN-2-YLAMINO) - acid and its pharmaceutically acceptable salts.
    [Show full text]
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0254920 A1 Delong Et Al
    US 20070254920A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0254920 A1 deLong et al. (43) Pub. Date: Nov. 1, 2007 (54) PRODRUG DERIVATIVES OF ACIDS USING (52) U.S. Cl. ......................... 514/319; 514/323: 514/573; ALCOHOLS WITH HOMOTOPIC HYDROXY 514/415: 514/443; 514/469; GROUPS AND METHODS FOR THEIR 546/196; 546/201: 546/206; PREPARATION AND USE 548/495; 549/49; 549/462 (75) Inventors: Mitchell A. deLong, Raleigh, NC (US); (57) ABSTRACT Jill M. McFadden, Chapel Hill, NC This invention relates to novel homotopic prodrugs and (US); Susan M. Royalty, Cary, NC medicaments and methods for their preparation, testing and (US); Eric J. Toone, Durham, NC use. In one embodiment, the homotopic prodrug has the (US); Jeffrey D. Yingling, Apex, NC general formula (US) Correspondence Address: O MICHAEL BEST & FRIEDRCH LLP 100 E WISCONSNAVENUE Rb, Suite 3300 --- MILWAUKEE, WI 53202 (US) wherein (73) Assignee: Aerie Pharmaceuticals, Inc., Research Triangle Park, NC (21) Appl. No.: 11/412,207 (22) Filed: Apr. 26, 2006 -- Publication Classification is a biologically-active moiety comprising a carboxylic acid functional group, and R is a homotopically-symmetrical (51) Int. Cl. alcohol bonded to the biologically-active moiety through the A6 IK 3/558 (2006.01) carboxylic acid functional group to form an ester linkage, as CO7D 409/02 (2006.01) well as optical isomers, enantiomers, pharmaceutically CO7D 405/02 (2006.01) acceptable salts, biohydrolyzable amides, esters, and imides CO7D 403/02 (2006.01) thereof and combinations thereof. US 2007/0254920 A1 Nov. 1, 2007 PRODRUG DERVATIVES OF ACDS USING WO 99/12896, and WO 99/12898.) However, such modifi ALCOHOLS WITH HOMOTOPIC HYDROXY cations have either resulted in only modest increases in GROUPS AND METHODS FOR THEIR half-life or resulted in compounds with diminished potency.
    [Show full text]
  • Thermodynamic Quantities for the Ionization Reactions of Buffers
    Thermodynamic Quantities for the Ionization Reactions of Buffers Robert N. Goldberg,a… Nand Kishore,b… and Rebecca M. Lennen Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899 ͑Received 21 June 2001; accepted 16 September 2001; published 24 April 2002͒ This review contains selected values of thermodynamic quantities for the aqueous ionization reactions of 64 buffers, many of which are used in biological research. Since the aim is to be able to predict values of the ionization constant at temperatures not too far from ambient, the thermodynamic quantities which are tabulated are the pK, standard ⌬ ؠ ⌬ molar Gibbs energy rG , standard molar enthalpy rH°, and standard molar heat ca- ؠ ⌬ pacity change rC p for each of the ionization reactions at the temperature T ϭ298.15 K and the pressure pϭ0.1 MPa. The standard state is the hypothetical ideal solution of unit molality. The chemical name͑s͒ and CAS registry number, structure, empirical formula, and molecular weight are given for each buffer considered herein. The selection of the values of the thermodynamic quantities for each buffer is discussed. © 2002 by the U.S. Secretary of Commerce on behalf of the United States. All rights reserved. Key words: buffers; enthalpy; equilibrium constant; evaluated data; Gibbs free energy; heat capacity; ionization; pK; thermodynamic properties. Contents 7.19. CAPSO.............................. 263 7.20. Carbonate............................ 264 7.21. CHES............................... 264 1. Introduction................................ 232 7.22. Citrate............................... 265 2. Thermodynamic Background.................. 233 7.23. L-Cysteine............................ 268 3. Presentation of Data......................... 234 7.24. Diethanolamine........................ 270 4. Evaluation of Data. ........................ 235 7.25. Diglycolate..........................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,304,086 B2 Schilling Et Al
    USOO7304086B2 (12) United States Patent (10) Patent No.: US 7,304,086 B2 Schilling et al. (45) Date of Patent: *Dec. 4, 2007 (54) INHIBITORS OF GLUTAMINYL CYCLASE WO WOOO,53596 9, 2000 WO WO O1/34594 A1 5, 2001 (75) Inventors: Stephan Schilling, Halle/Saale (DE); WO WO O2, 13821 2, 2002 WO WO O2, 16318 A1 2, 2002 Mirko Buchholz, Halle/Saale (DE): WO WO O2O16318 A1 * 2/2002 Andre Johannes Niestroj, Sennewitz WO WO O2/O66459 A1 8, 2002 (DE); Ulrich Heiser, Halle/Saale (DE): WO WO O2/O92103 A1 11 2002 Hans-Ulrich Demuth, Halle/Saale (DE) WO WO O2O94813 A1 * 11/2002 WO WO 03/04.0174 A2 5, 2003 (73) Assignee: Probiodrug AG, Halle/Saale (DE) WO WO O3,O70732 8, 2003 WO WO O3068738 8, 2003 (*) Notice: Subject to any disclaimer, the term of this WO WO O30954.21 A1 * 11/2003 patent is extended or adjusted under 35 WO WO 2004O26815 A2 * 4, 2004 U.S.C. 154(b) by 20 days. WO WO 2004/089366 10, 2004 WO WO 2004/098591 A2 11 2004 This patent is Subject to a terminal dis WO WO 2004/098.625 A2 11 2004 claimer. OTHER PUBLICATIONS (21) Appl. No.: 11/051,760 Haley et al. Giorn. Ital. Chemioterap. (1962) 6-9 (No. 3), 213-24. Abstract from CAS attached. (22) Filed: Feb. 4, 2005 Hough et al. Pharmacology, Biochemistry and Behavior 1999, 65(1), 61-66. * Abstract from CAS attached.* (65) Prior Publication Data Morissette et al. Advanced Drug Delivery Reviews 2004, 56. US 2005/0215573 A1 Sep.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Buffers a Guide for the Preparation and Use of Buffers in Biological Systems Calbiochem® Buffers a Guide for the Preparation and Use of Buffers in Biological Systems
    Buffers A guide for the preparation and use of buffers in biological systems Calbiochem® Buffers A guide for the preparation and use of buffers in biological systems Chandra Mohan, Ph.D. EMD, San Diego, California © EMD, an affiliate of Merck KGaA, Darmstadt, Germany. All rights reserved. A word to our valued customers We are pleased to present to you the newest edition of Buffers: A Guide for the Preparation and Use of Buffers in Biological Systems. This practical resource has been especially revamped for use by researchers in the biological sciences. This publication is a part of our continuing commitment to provide useful product information and exceptional service to you, our customers. You will find this booklet a highly useful resource, whether you are just beginning your research work or training the newest researchers in your laboratory. Over the past several years, EMD Biosciences has clearly emerged as a world leader in providing highly innovative products for your research needs in Signal Transduction, including the areas of Cancer Biology, Alzheimer’s Disease, Diabetes, Hypertension, Inflammation, and Apoptosis. Please call us today for a free copy of our LATEST Catalog that includes tools for signal transduction and life science research. If you have used our products in the past, we thank you for your support and confidence in our products, and if you are just beginning your research career, please call us and give us the opportunity to demonstrate our exceptional customer and technical service. Corrine Fetherston Sr. Director, Marketing ii Table of Contents: Why does Calbiochem® Biochemicals Publish a Booklet on Buffers? .
    [Show full text]
  • Survey and Risk Assessment of Chemical Substances in Deodorants
    Survey and risk assessment of chemical substances in deodorants Suresh C. Rastogi & Gitte Hellerup Jensen National Environmental Research Institute Jeanne Duus Johansen National Allergy Research Centre Survey of Chemical Substances in Consumer Products, No. 86 2007 The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents SAMMENFATNING 5 SUMMARY 7 1 INTRODUCTION 11 2 MARKET SURVEY AND PRODUCT SAMPLING 13 2.1 MARKET SURVEY 13 2.2 LEGISLATION 15 2.3 SAMPLING OF PRODUCTS AND CONTROL OF LABELLING 15 2.4 SELECTION OF PRODUCTS FOR ANALYSIS 18 3 ANALYSIS 19 3.1 MATERIALS 19 3.2 ANALYSIS 19 3.2.1 Sample preparation 19 3.2.2 Analysis of fragrance substances 19 3.2.3 Analysis of triclosan 20 4 RESULTS 21 5 RISK ASSESSMENT 27 5.1 DEODORANTS AND CONTACT ALLERGY 27 5.2 RISK ASSESSMENT – IN GENERAL 27 5.3 THE SELECTED FRAGRANCE SUBSTANCES 28 5.3.1 HYDOXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE (HICC) 28 5.3.2 HYDROXYCITRONELLAL 32 5.3.3 ISOEUGENOL 33 5.3.4 CINNAMAL/CINNAMYL ALCOHOL 34 5.4 FARNESOL 35 5.5 COMMENTS CONCERNING OTHER FRAGRANCE SUBSTANCES 35 5.6 ALLERGEN LOAD OF FRAGRANCE SUBSTANCES 36 5.7 TRICLOSAN 36 6 DISCUSSION 38 7 REFERENCES 43 ANNEX 1 49 3 4 Sammenfatning Deodoranter anvendes dagligt af store dele af befolkningen og kan indeholde ingredienser, som visse duftstoffer og konserveringsmidler, der er hyppige år- sager til hudallergi.
    [Show full text]
  • (From the Department of Physiology, University of Minnesota, Minneapolis) Same Journal. N. K., Kolloid-Z., 1929, 47, 101. the Jo
    THE STRUCTURE OF THE COLLODION MEMBRANE AND ITS ELECTRICAL BEHAVIOR II, THE ACTIVATED COLLODION MEMBRANE BY KARL SOLLNER, IRVING ABRAMS, AND CHARLES W. CARR (From the Department of Physiology, University of Minnesota, Minneapolis) (Received for pubfication, March 31, 1941) I In preceding communicationst, 2 we were led to the conclusion that the elec- trochemical activity of collodion membranes, as manifested by concentration potentials, etc., is due principally to acidic impurities. Accordingly, different brands of collodion differ widely as to their activity, the purer brands being less active. The impure (but active) foreign brands of collodion, heretofore generally used by workers in the field of electrochemical membrane investiga- tion, are no longer obtainable. In order to continue our investigation, it became necessary to find methods to produce active collodion membranes at will. The idea of inducing changes in the electrochemical characteristics of mem- branes is not entirely new. Many investigators have activated membranes by the adsorption of proteins, e.g. the proteinized membranes of Loeb. 8 Other investigators use other organic compounds, usually dyestuffs. These may be adsorbed like proteins or they may be dissolved in the collodion solution* pre- vious to casting the membranes. Such membranes are interesting and useful in their own right, but are not altogether satisfactory substitutes for active collodion membranes. They very often show considerable asymmetry; more- over, the dyestuffs so far employed (according to the literature) are slowly re- leased into the solution in contact with the membrane, whereby the character of the membrane is considerably changed. Meyer and Sievers5 used an oxida- tion method to activate a cellophane membrane.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann Et Al
    US 2014O127257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann et al. (43) Pub. Date: May 8, 2014 (54) DERMATOLOGICALLY EFFECTIVE YEAST Publication Classification EXTRACT (51) Int. Cl. (75) Inventors: Yvonne Schiemann, Essen (DE); Mike A61E36/064 (2006.01) Farwick, Essen (DE); Thomas Haas, CI2P I/02 (2006.01) Muenster (DE); Mirja Wessel, Bochum A61E36/06 (2006.01) (DE) (52) U.S. Cl. CPC ............... A61K 36/064 (2013.01); A61K 36/06 (73) Assignee: EVONIK DEGUSSA GMBH, Essen (2013.01); CI2P I/02 (2013.01) (DE) USPC ...................................... 424/195.16; 435/171 (21) Appl. No.: 14/128,244 (22) PCT Fled: Jun. 14, 2012 (57) ABSTRACT (86) PCT NO.: PCT/EP2012/061263 The invention relates to a method for producing a dermato S371 (c)(1), logically active yeast extract, comprising the following steps: (2), (4) Date: Dec. 20, 2013 providing a preculture of the yeast cells, culturing the cells for (30) Foreign Application Priority Data at least fifteen minutes at a pH of 1.8-4, harvesting the cells and lysing the cells, and a yeast extract produced thereby and Jun. 29, 2011 (EP) .................................. 11171953.0 products comprising said yeast extract. Patent Application Publication May 8, 2014 Sheet 1 of 3 US 2014/O127257 A1 -0-Yarrowia------------ lipolytica -- Pichia CBS 1991 - A - Saccharomyces Cerevisiae Fig. 1 US 2014/O127257 A1 May 8, 2014 DERMATOLOGICALLY EFFECTIVE YEAST skin. Against the background of consumers’ uncertainty with EXTRACT respect to genetic engineering techniques, there is a particular demand for corresponding agents that can be regarded, 0001.
    [Show full text]
  • Biological Buffers and Ultra Pure Reagents
    Biological Buffers and Ultra Pure Reagents Are MP Buffers in your corner? One Call. One Source. A World of Ultra Pure Biochemicals. www.mpbio.com Theoretical Considerations Since buffers are essential for controlling the pH in many Since, under equilibrium conditions, the rates of dissociation and biological and biochemical reactions, it is important to have a association must be equal, they may be expressed as: basic understanding of how buffers control the hydrogen ion concentration. Although a lengthy, detailed discussion is impractical, + - k1 (HAc) = k2 (H ) (Ac ) some explanation of the buffering phenomena is important. Or Let us begin with a discussion of the equilibrium constant (K) for + - weak acids and bases. Acids and bases which do not completely k1 = (H ) (Ac ) dissociate in solution, but instead exist as an equilibrium mixture of k (HAc) undissociated and dissociated species, are termed weak acids and 2 bases. The most common example of a weak acid is acetic acid. If we now let k1/k2 = Ka , the equilibrium constant, the equilibrium In solution, acetic acid exists as an equilibrium mixture of acetate expression becomes: ions, hydrogen ions, and undissociated acetic acid. The equilibrium between these species may be expressed as follows: + - Ka = (H ) (Ac ) k1 (HAc) + - HAc ⇌ H + Ac which may be rearranged to express the hydrogen ion concentration k2 in terms of the equilibrium constant and the concentrations of undissociated acetic acid and acetate ions as follows: where k1 is the dissociation rate constant of acetic acid to acetate and hydrogen ions and k is the association rate constant of the ion 2 (H+) = K (HAc) species to form acetic acid.
    [Show full text]